Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction

In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes. ABSTRACT Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners. Our prediction model based on gut microbiome for IBD diagnosis is robust across the cohorts, which showed 87.5% and 79.1% prediction accuracy in Crohn’s disease (CD) and ulcerative colitis (UC) patients, respectively. A relative increase in the levels of Actinobacteria and Proteobacteria (Enterobacteriaceae) and a relative decrease in the levels of Firmicutes (Clostridiales) were strongly correlated with IBD severity (P < 0.05). Additionally, restoration of gut microbiota diversity and a significant increase in Clostridiales relative abundance were found in patients responding to infliximab (IFX [Remicade]) treatment compared to those in relapse. Moreover, certain microbes, mainly Clostridiales, predicted the treatment effectiveness with 86.5% accuracy alone and 93.8% accuracy in combination with calprotectin levels and Crohn’s disease activity index (CDAI). Taking the results together, we conclude that gut microbiota can offer a set of universal biomarkers for diagnosis, disease activity evaluation, and infliximab treatment response prediction in IBD. IMPORTANCE In the present report, we show that the human fecal microbiota contains promising and universal biomarkers for the noninvasive evaluation of inflammatory bowel disease severity and IFX treatment efficacy, emphasizing the potential ability to mine the gut microbiota as a modality to stratify IBD patients and apply personalized therapy for optimal outcomes.

[1]  S. Riordan,et al.  Effects of Anti-Cytokine Antibodies on Gut Barrier Function , 2019, Mediators of inflammation.

[2]  I. Skrypnyk.  Inflammatory bowel diseases; 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) , 2019, Modern Gastroenterology.

[3]  R. Luiz,et al.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil , 2018, The European Journal of Health Economics.

[4]  K. Chi.  Epidemiology: Rising in the East , 2016, Nature.

[5]  R. Xavier,et al.  Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease , 2016, Science.

[6]  Martin J. Blaser,et al.  Helminth infection promotes colonization resistance via type 2 immunity , 2016, Science.

[7]  Hong Wang,et al.  Infliximab for the treatment of Crohn’s disease: efficacy and safety in a Chinese single-center retrospective study , 2015, European journal of gastroenterology & hepatology.

[8]  Judy H. Cho,et al.  Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations , 2015, Nature Genetics.

[9]  J. Kabeerdoss,et al.  Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid , 2015, The Indian journal of medical research.

[10]  E. Zoetendal,et al.  Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation , 2015, The American Journal of Gastroenterology.

[11]  R. Knight,et al.  Meta‐analyses of human gut microbes associated with obesity and IBD , 2014, FEBS letters.

[12]  S. Ng,et al.  Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific , 2014, Gut.

[13]  Youlian Zhou,et al.  Efficacy and safety of infliximab in treating patients with ulcerative colitis: Experiences from a single medical center in southern China , 2014, Journal of digestive diseases.

[14]  S. Ng,et al.  Characteristics of Fecal and Mucosa-Associated Microbiota in Chinese Patients With Inflammatory Bowel Disease , 2014, Medicine.

[15]  E. Louis,et al.  Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease , 2014, Inflammatory bowel diseases.

[16]  K. Ray.  IBD: Understanding gut microbiota in new-onset Crohn's disease , 2014, Nature Reviews Gastroenterology &Hepatology.

[17]  Se Jin Song,et al.  The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.

[18]  Hong-Wei Zhou,et al.  Comparison of direct boiling method with commercial kits for extracting fecal microbiome DNA by Illumina sequencing of 16S rRNA tags. , 2013, Journal of microbiological methods.

[19]  S. Ng,et al.  Impact of Ethnicity, Geography, and Disease on the Microbiota in Health and Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[20]  Jesse R. Zaneveld,et al.  Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences , 2013, Nature Biotechnology.

[21]  S. Ng,et al.  Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. , 2013, Gastroenterology.

[22]  T. Wiele,et al.  Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model , 2012, The ISME Journal.

[23]  S. Winter,et al.  The dynamics of gut‐associated microbial communities during inflammation , 2013, EMBO reports.

[24]  Xin Wang,et al.  The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. , 2013, Diagnostic microbiology and infectious disease.

[25]  Jing-Long Huang,et al.  Fecal Calprotectin as a Correlative Marker in Clinical Severity of Infectious Diarrhea and Usefulness in Evaluating Bacterial or Viral Pathogens in Children , 2012, Journal of pediatric gastroenterology and nutrition.

[26]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[27]  Ren Mao,et al.  Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta‐analysis of prospective studies , 2012, Inflammatory bowel diseases.

[28]  Francisco Guarner,et al.  The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.

[29]  Clarence K. Wong,et al.  Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. , 2012, World journal of gastroenterology.

[30]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[31]  Eric J. Alm,et al.  Non-Invasive Mapping of the Gastrointestinal Microbiota Identifies Children with Inflammatory Bowel Disease , 2012, PloS one.

[32]  T. Matsui,et al.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.

[33]  J. Clemente,et al.  Human gut microbiome viewed across age and geography , 2012, Nature.

[34]  Eric P. Nawrocki,et al.  An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea , 2011, The ISME Journal.

[35]  C. Huttenhower,et al.  Metagenomic biomarker discovery and explanation , 2011, Genome Biology.

[36]  Philippe Seksik,et al.  Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.

[37]  J. Lewis.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.

[38]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[39]  K. Honda,et al.  Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.

[40]  N. Pace,et al.  Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[41]  O. Inatomi,et al.  Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis , 2011, Journal of Gastroenterology.

[42]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[43]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[44]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[45]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[46]  P. Gionchetti,et al.  Infliximab in the treatment of Crohn’s disease , 2007, Therapeutics and clinical risk management.

[47]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[48]  S. Dorn.  Predictors of Crohn's disease. , 2006, Gastroenterology.

[49]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[50]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[51]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[52]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[53]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[54]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[55]  J. Hampe,et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.

[56]  M. Cappa,et al.  Does Graves’ Disease during Puberty Influence Adult Bone Mineral Density? , 2002, Hormone Research in Paediatrics.

[57]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[58]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[59]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[60]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.

[61]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[62]  J. D. Wager,et al.  The effect of lactulose, pectin, arabinogalactan and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system , 1990, British Journal of Nutrition.

[63]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.